Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Cut by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 468,594 shares of the medical research company’s stock after selling 8,557 shares during the period. Bank of New York Mellon Corp’s holdings in Charles River Laboratories International were worth $86,503,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in Charles River Laboratories International by 74.6% during the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 9,830 shares of the medical research company’s stock worth $1,815,000 after acquiring an additional 4,200 shares during the period. Olympiad Research LP acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $267,000. VisionPoint Advisory Group LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $1,751,000. Handelsbanken Fonder AB grew its stake in shares of Charles River Laboratories International by 1.6% in the 4th quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company’s stock worth $2,296,000 after purchasing an additional 200 shares during the last quarter. Finally, Bryn Mawr Capital Management LLC raised its holdings in shares of Charles River Laboratories International by 1,871.2% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 35,659 shares of the medical research company’s stock worth $6,583,000 after purchasing an additional 33,850 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on CRL shares. TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. UBS Group restated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Finally, William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $195.71.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $165.01 on Monday. The business’s 50-day moving average is $170.94 and its 200-day moving average is $186.85. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of 1,100.04, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the prior year, the business earned $2.46 EPS. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).